Document is current

Any future updates will be listed below

Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study

Crossref DOI link: https://doi.org/10.1186/s12885-016-2523-7

Published Online: 2016-07-26

Published Print: 2016-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark